4 Pilot study results: Murr AH, Smith TL, Hwang PH, et al. IFAR. 2011;1:23–32.; ADVANCE II clinical trial: Marple BF, Smith TL, Han JK et al. Otolaryngol Head Neck Surg.2012; 146(6) 1004-1011.; Meta-analysis: Han JK, Marple BF, Smith TL et al IFAR. 2012; 2 :271-279.
5 Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000;110:29–31.
[i] Stankiewicz J, Truitt T, Atkins J, Winegar B, Cink P, Raviv J, Henderson D, Tami T. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. 2012 May; 2(3): 199-206.
[ii] Stankiewicz J, Tami T, Truitt T, Atkins J, Liepert D, Winger B. Transantral, endoscopically guided balloon dilatation of the ostiomeatal complex for chronic rhinosinusitis under local anesthesia. Am J of Rhinology. 2009 May-June; 321-327.
[iii] Gould, J. In-office balloon dilation: Procedure techniques and outcomes using a malleable multi-sinus dilation tool. ENT Journal. Vendome Healthcare Media, 19 Dec 2012.
[iv] Stankiewicz J, Truitt T, Atkins J, Winegar B, Cink P, Raviv J, Henderson D, Tami T. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. 2012 May; 2(3): 199-206
The benefits of office sinus dilation include:
Office sinus dilation is a minimally invasive option that can be performed by Dr. Neal right here, in our offices. The goal of office sinus dilation is to reshape anatomy to expand sinus pathways and restore drainage.
The procedure utilizes small balloons placed in key places in the nose and sinus, which are then dilated to expand the sinus pathways. It may be an effective, lasting option for some patients whose symptoms do not resolve with medication.
Harrisonburg ENT Associates
Chronic Sinusitis Patients Have A New Weapon - PROPEL
The dissolveable PROPEL Steroid-Releasing Implant is the first in a new category of products offering localized, controlled delivery of steroid directly to the sinus tissue to maintain the openings created in surgery.
Applying principles of coronary drug-eluting stents to sinusitis sufferers, the spring-link implants gradually deliver an advanced steroid with anti-inflammatory properties (mometasone furoate) directly to the sinus lining, then dissolve into the body following endoscopic sinus surgery. The result is improved surgical outcomes, reducing the need for additional surgical procedures and for systematic steroids, which can have serious side effects.
Three rigorous clinical trials4 have demonstrated that the implant is safe and maintains the results of sinus surgery by propping open the sinus cavities and decreasing post-operative scarring and inflammation. Reducing these factors is proven to improve long-term outcomes5 and to reduce the need for repeat surgery and oral steroids, which can have serious side effects. PROPEL is the only product used in sinus surgery to be supported by level 1-A evidence.